Price T Rowe Associates Inc Lineage Cell Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 165,394 shares of LCTX stock, worth $138,930. This represents 0.0% of its overall portfolio holdings.
Number of Shares
165,394
Previous 161,314
2.53%
Holding current value
$138,930
Previous $239,000
31.38%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.3MCall Options Held
31.3KPut Options Held
400-
Broadwood Capital Inc New York, NY41.7MShares$35 Million3.19% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$8.03 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.47MShares$7.12 Million0.0% of portfolio
-
Defender Capital, Llc.4.97MShares$4.18 Million1.77% of portfolio
-
Logos Global Management LP San Francisco, CA4.7MShares$3.95 Million0.44% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $143M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...